Merck Serono Begins MS Oral Therapy Trial
Posted on: Wednesday, 24 January 2007, 12:01 CST
Merck Serono has begun a phase II study that will evaluate two dose regimens of its oral formulation of cladribine when added to a new formulation of Rebif in multiple sclerosis patients.
The study will examine the safety, tolerability and effectiveness of oral cladribine combined with a new formulation of Rebif in multiple sclerosis patients with active disease despite treatment with Rebif. The primary efficacy endpoint is the mean change in the number of new T1 gadolinium-enhanced lesions per subject per magnetic resonance imaging (MRI) scan from baseline to 96 weeks.
Oral cladribine is currently also evaluated as a monotherapy in a phase III trial for first-line treatment of relapsing forms of multiple sclerosis. The new formulation of Rebif is under review by the European Medicines Agency, the FDA and other healthcare authorities.
"The different mechanism of action and the oral intermittent administration of oral cladribine make it a potentially useful add-on therapy to Rebif at a critical time of disease progression," said Bruno Musch, Merck Serono's head of Neurology Clinical Development.
If approved, oral cladribine would become the first oral therapy for first-line treatment of multiple sclerosis.
Source: Datamonitor
Related Articles
- EMD Serono Submits Application for Cladribine Tablets as a Potential Oral Short-Course Multiple Sclerosis Therapy in the United States
- Launch of Highly Anticipated Oral Agents and Increasing Use of Current and Emerging Injectable Drugs Will Drive the Multiple Sclerosis Drug Market to Nearly $10 Billion in 2018
- Surveyed Neurologists Anticipate That Less Than 30 Percent of Their Use of Emerging Oral Agents in Multiple Sclerosis Will be in the First Line
- Opexa Reports Top-Line Data From Phase IIb Multiple Sclerosis Study
- Teva to Present New Treatment Data at World Congress for Multiple Sclerosis
- Merck Serono Has Initiated the ONWARD Study to Evaluate Oral Cladribine As Add-on Treatment for Multiple Sclerosis
- Biogen Idec Initiates Phase III Clinical Program of Oral Compound BG-12 for Multiple Sclerosis
- Critical Outcome Technologies Inc. Announces the Final Selection of Its Library of Orally Available Lead Compounds for the Treatment of Acute Multiple Sclerosis
- Serono's Oral Cladribine for the Treatment of Multiple Sclerosis Awarded Fast Track Status By FDA
- Phase II Data Showing Clinical Benefits of Novel Once-Daily Oral Multiple Sclerosis Therapy FTY720 (Fingolimod) Published in New England Journal of Medicine
 |
 |
User Comments (0)
RSS Feeds